UBS Group
QNCX icon

UBS Group’s Quince Therapeutics QNCX Stock Holding History

UBS Group’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-251
Closed -$4.6M – 10609
2021
Q3 		$4.6M Buy
+251
New +$3.99M ﹤0.01% 2755

Other funds holding QNCX

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's QNCX Position: Q2 2026 in Review

UBS Group increased its Quince Therapeutics (QNCX) stake by 157,567% in Q2 2026, buying an estimated $109K and bringing the position to 4,730 shares worth $86K. The position accounts for ﹤0.01% of the portfolio, ranked #7268.

UBS Group first reported a position in QNCX in Q2 2019 and has held it in 29 quarters since. The position peaked at $1.56M in Q3 2021. 26 funds tracked by Wall St. Rank hold QNCX as of Q2 2026.

  • UBS Group held 4,730 shares of Quince Therapeutics worth $86K as of Q2 2026.
  • UBS Group bought 4,727 Quince Therapeutics shares in Q2 2026, an estimated $109K.
  • Quince Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #7268 holding.
  • UBS Group first reported a position in Quince Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • UBS Group's Quince Therapeutics position peaked at $1.56M in Q3 2021.
  • 26 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.